about
Induced immunity against hepatitis B virusScreening and cloning for proteins transactivated by the PS1TP5 protein of hepatitis B virus: a suppression subtractive hybridization studyImmune responses to HBsAg conjugated to protein D of non-typeable Haemophilus influenzae in miceStudy of transactivating effect of pre-S2 protein of hepatitis B virus and cloning of genes transactivated by pre-S2 protein with suppression subtractive hybridization.A pilot clinical trial of a recombinant ricin vaccine in normal humans.A polymer/oil based nanovaccine as a single-dose immunization approach.A new vaccine escape mutant of hepatitis B virus causes occult infection.Serum levels of preS antigen (HBpreSAg) in chronic hepatitis B virus infected patients.Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.Hepatitis B Seroprotection and the Response to a Challenging Dose among Vaccinated Children in Red Sea GovernorateMedical virology of hepatitis B: how it began and where we are nowPreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac vaccine and their relation to the antibody response to hepatitis B surface antigen.A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy.Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy.Efficacy of the vaccination in inflammatory bowel disease.Approach and management of patients with chronic hepatitis B and C during the course of inflammatory bowel disease.Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine.Biomedical applications of yeast- a patent view, part one: yeasts as workhorses for the production of therapeutics and vaccines.Immune Evasion Strategies during Chronic Hepatitis B and C Virus InfectionDeliberate manipulation of the surface hydrophobicity of an adsorbent for an efficient purification of a giant molecule with multiple subunits.CD4+ T helper cell responses against human bocavirus viral protein 2 viruslike particles in healthy adults.Dengue-specific subviral nanoparticles: design, creation and characterization.Non-responsiveness to hepatitis B surface antigen vaccines is not caused by defective antigen presentation or a lack of B7 co-stimulation.Development of the CpG Adjuvant 1018: A Case Study.British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015.The efficacy of accelerated, multiple, double-dose hepatitis B vaccine against hepatitis B virus infection in cancer patients receiving chemotherapy.Highly versatile immunostimulating nanocapsules for specific immune potentiation.Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: a retrospective study.Expression and purification of the complete PreS region of hepatitis B Virus.Brazilian hepatitis B vaccine: a six-year follow-up in adolescents.Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease.Prevention of hepatitis B virus infection by vaccination: Progress and problems.Polymeric Nanocapsules for Vaccine Delivery: Influence of the Polymeric Shell on the Interaction With the Immune System.Hepatitis B vaccine: Using skin when muscle does not work
P2860
Q28080525-A74ED88A-FEA8-4953-BDE0-791BDBF1F0A4Q28299559-40E4CCA2-A953-46BE-9807-D65469C44C03Q28543439-4C91AC8D-5F2F-46F7-A4FB-200F7163946BQ30864670-9AA91911-ADFD-4776-A5FE-5740A8D837F4Q34479216-B01B1879-CF78-4453-9E36-A6262FA48FF1Q34685874-AA6D1956-6264-4C6A-A5C7-99391641A213Q35887509-99C12D22-AC79-4D8E-B9BA-5C38056E2C68Q36151267-05A3DAF3-6958-4875-934A-B29047BDBB8FQ36752181-AD1E7F3B-1415-4813-AED0-226D05E010D9Q37006564-65AD0997-A46F-467B-B253-10665360001CQ37059714-2FDE087A-41C5-4BFB-89F1-72DBFF918821Q37082600-20006524-572F-43BD-AF5B-C5791DAC7824Q37678199-02EEEE25-3DBD-47A2-8E96-159AD2E6E50CQ37867099-E9783596-6547-4D8D-958E-F2B79F4AAA6CQ38094023-70FC9839-20E3-458D-B0E3-E248A64DA55BQ38235053-F266F477-88E0-44C2-BC95-446AB8FC14E9Q38306933-D73A5114-BAB3-42EC-ACE5-60EE3DB371C6Q38671575-21397D0D-CA2B-4D3F-AA44-421E3FC337FDQ39327457-48685384-983F-409F-B91C-27645E505340Q39455713-B4F84832-9F12-4049-A6B3-F863255A488BQ39933213-3E3379B4-FA12-404E-80D0-CEF7B5F83744Q40246595-8C5F524F-6F4F-41B0-8D8A-21E913CBE632Q40447718-1E9F27AE-704A-4C11-993D-CDB2CFBC2F9BQ40549653-19CAC686-1160-477F-B8AD-8AF8819C34E7Q40560650-E80323BD-1790-4DE9-B094-3DD8BF961CA3Q40924415-720D9CC7-C4B2-4533-A297-742E47224F92Q42228751-261D371E-36A5-49B6-BD83-3139C7661EE1Q42267006-5EA9A881-59A8-4F19-AEB4-C5F7853A8FE8Q43118638-D1E30EE6-1CB9-4290-9128-5AAC0A55531FQ44666849-7C7E2C4E-882A-4685-B09B-8B14AB8AADC5Q45358091-5545FC59-0C04-44BF-8739-15555DE09427Q45402181-2B838AF5-FFA8-4551-9D73-7CFF9BFA6DFEQ55146328-885C84E1-6C3A-4341-91DF-35E6F22EA194Q57071372-CAB11AEB-91A5-4DF0-8DB6-93C5B8CB75A1
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Hepatitis B vaccines.
@ast
Hepatitis B vaccines.
@en
type
label
Hepatitis B vaccines.
@ast
Hepatitis B vaccines.
@en
prefLabel
Hepatitis B vaccines.
@ast
Hepatitis B vaccines.
@en
P1476
Hepatitis B vaccines.
@en
P2093
Daniel Shouval
P356
10.1016/S0168-8278(03)00152-1
P478
39 Suppl 1
P577
2003-01-01T00:00:00Z